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Background: Myxofibrosarcoma comprises a spectrum of malignant neoplasms withprominent myxoid stromata,
cellular pleomorphism, and distinct curvilinear vascular patterns. These neoplasms mainly affect patients in the sixth
to eighth decades of life and the overall 5-year survival rate is 60–70%.
Methods: After the establishment of the novel myxofibrosarcoma cell lines MUG-Myx1, cells were characterized
using short tandem repeat (STR), copy number variation (CNV), and genotype/loss-of-heterozygosity (LOH) analyses.
The growth behaviour of the cells was analyzed with the xCELLigence system and an MTS assay. The tumourigenicity
of MUG-Myx1 was proved in NOD/SCID mice. Additionally, a stem-like cell population with high enzymatic activity
of aldehyde dehydrogenase 1 (ALDH1high) was isolated for the first time from myxofibrosarcoma cells using the
Aldefluor® assay followed by FACS analysis.
Results: The frozen primary parental tumour tissue and the MUG-Myx1 cell line showed the same STR profile at
the markers D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D,
Amelogenin, D8S1179, TPOX, and FGY. Typically, myxofibrosarcoma gain and/or amplification was mapped to
7p21.3-q31.1, q31.1-q31.33, q33-q36.2, p21.3, p21.2, p14.1-q11.23, q31.33-q33, p21.2-p14.1, q11.23-q21.3, q36.2-q36.3,
which, respectively are known to harbour tumour-associated genes, including TIF, BRAF, MLL3, SMO, and MET.
Typically an LOH for myxofibrosarcoma on chr5 q21 was found. In addition, MUG-Myx1 ALDH1high cells showed an
upregulation of the ABC transporter ABCB1 and ABCG2; higher c-Myc, E-cadherin and SOX-2 expression; and a
higher potential for tumourigenicity and proliferation levels.
Conclusion: The new myxofibrosarcoma cell line MUG-Myx1 was established to enrich the bank of publicly
available cell lines, with respect to providing comprehensive genetic and epigenetic characterization. Furthermore,
because of their tumourigenicity, the cell line is also suitable for in vivo experiments.
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Myxofibrosarcoma is the most common sarcoma in
elderly patients and is characterized histologically by a
multinodular growth pattern and variably prominent
myxoid stroma. The tumour is mainly composed of
spindle cells with variable cytologic atypia accentuated
along curvilinear vessels [1]. Clinically, increasing grades
and stages of the tumors are frequently seen in myxofibro-
sarcomas after relentless local recurrences, which may
eventually lead to metastatic diseases [1-3]. Recurrence
has been shown to occur in spite of repeated surgery in-
volving wide local excisions and negative surgical margins
[2]. Furthermore, metastatic myxofibrosarcomas are often
refractory to current treatment strategies and constitute
the primary cause of sarcoma-related death [1,3,4].
Permanent cell lines derived from primary sarcomas
offer the opportunity to study functional alterations in
sarcoma biology. The new myxofibrosarcoma cell line
MUG-Myx1 was established to enrich the bank of publicly
available cell lines, allowing comprehensive genetic and
epigenetic characterization. Furthermore, because of their
tumourigenicity, the cell line is also suitable for in vivo
experiments. To develop novel prognostic adjuncts and
therapeutic interventions, it is of paramount importance
to elucidate the molecular determinants correlated with
tumour aggressiveness and metastatic spread in myxofi-
brosarcoma progression. Important factors in potential
therapeutic benefits are cancer stem cells (CSCs), which
are defined as cells within a tumour that possess the
capacity to renew themselves and generate the heteroge-
neous lineages of cancer cells that comprise the tumour
[5,6]. Ginestier et al. showed that aldehyde dehydrogenase
1 (ALDH1) is a marker of normal and malignant human
mammary stem cells and a predictor of a poor clinical out-
come for breast cancer patients [7]. High ALDH1 activity
characterises stem cell populations in many cancer types
including human multiple myeloma, pancreatic cancer,
breast cancer, and soft tissue sarcomas [8-10].
The present study describes the clinical, morphologic,
and cytogenetic features of the newly established myxofi-
brosarcoma cell line, MUG-Myx1. An Aldefluor® assay
and fluorescence-activated cell sorting (FACS) analysis
were used to isolate stem-like ALDH1high cells and
ALDH1low cells. Furthermore, we analysed the two sub-
populations for their cell proliferation properties, ex-




A 66-year-old Caucasian man presented himself at the
Department of Orthopaedic Surgery, at the Medical
University of Graz, Austria, in April 2010 after an intra-
lesional resection of a myxofibrosarcoma G3 on the leftventral thorax conducted at an outside institution. Radiog-
raphy and magnetic resonance imaging (MRI) revealed
postoperative haemato-seroma. Computer tomography of
the thorax, abdomen and pelvis revealed no further le-
sions. In the same month, a wide resection was performed
at our department and the thorax was reconstructed with
a prolene net. A postoperative histopathological evaluation
revealed a myxofibrosarcoma G3 with the resection
margins free of disease. Postoperative chemotherapy
with Epirubicine and Iphosphamide was performed and,
in addition, radiotherapy was recommended. However,
the patient refused this treatment. The research reported
in this study was conducted adhering to the highest
principles of human welfare according to the Consort
declaration on clinical research design and the Helsinki
declaration on medical protocols and ethics. The study
protocol and the informed consent of the patients were
approved by the ethics committee of the Medical University
Graz (vote #20-430ex08/09; valid until 25.09.2013). The
patient was extensively informed and gave his written
approval.
Cell culture procedures
The tumour tissue was obtained immediately after surgical
removal. After mechanical disaggregation of the tumour
tissue into 1–2 mm3 pieces, the minced tissue was enzy-
matically digested with 2 mg/ml collagenase B (Roche
Diagnostics, Mannheim, Germany) for approximately
20 hours under constant rotation at 37°C. Cells were then
centrifuged at 1400 rpm for 5 min and washed twice with
PBS. Collected cells were plated in Dulbecco’s-modified
Eagle’s medium (DMEM-F12; Invitrogen, Darmstadt,
Germany), containing 10% foetal bovine serum (FBS;
Invitrogen), 1% L-glutamine (Invitrogen), 100 units/ml
penicillin (Invitrogen), 100 μg/ml streptomycin (Invitro-
gen) and 0.25 μg amphotericin B (PAA Laboratory, Pasch-
ing, Austria). Cells were kept at 37°C in a humidified
atmosphere of 5% CO2 and passaged by trypsination upon
reaching confluence. All cell cultures were periodically
checked for mycoplasma by PCR.
Immunohistochemical studies
Patient’s tumour
For the histopathological evaluation, the tumour was
tested using the streptavidin-biotin peroxidase complex
method with antibodies against Caldesmon (Dako,
Glostrup, Denmark), S100 (Dako), CD34 (Neomarkers,
Fremont, CA), Desmin, EMA, and Pan-CK (all Ventana
Medical Systems, Tucson, AZ).
MUG-Myx1 characterization
For IHC analysis, cells were seeded at a concentration of
1 × 104 cells on polystyrene culture slides (BD Biosciences,
San Diego, US). When cell cultures reached approximately
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exposure to formalin 4% for 10 minutes.
Cells were grown on culture slides (confluence 70–80%)
and fixed with acetone for 10 min at −20°C. After drying
and rehydration, the slides were treated with Large
Volume UltraV-Block (ThermoScientific, Waltham, US)
for 10 min at room temperature to block nonspecific
binding, incubated with the primary monoclonal mouse
anti-Vimentin antibody (Dako) for 30 min and, after
several washing steps, incubated with the Cy2 conju-
gated sheep anti-mouse IgG secondary antibody (Jackson
Immunoresearch, Suffolk, UK) at a dilution of 1:200
for 30 min. Nuclei were counterstained with DAPI
(Invitrogen).
SCID mice tissue
IHC studies using the streptavidin-biotin peroxidase
complex method were carried out on histological slides
from ALDH1high and ALDH1low SCID mice tumours,
employing an rabbit monoclonal primary antibody against
the anti-Ki-67 (clone 30–9) (Ventana Medical Systems)
using the BenchMark Ultra instrument (Ventana Medical
Systems). Slides were photographed using an Olympus
BX51 microscope with an Olympus DP71 microscope
digital camera. The stained slides were scanned digitally
and positive and negative cells were quantified using the
ImageScope software (ImageScope Virtual Slide, version
6.25, Aperio Technol.,Vista, US). Positivity was deter-




1 × 103, 5 × 103, and 1 × 104 MUG-Myx1 cells were
seeded into 96-well microtiter plates (Brand, Voerde-
Friedrichsfeld, Germany) and the CellTiter 96® AQueous
Assay (Promega, Mannheim, Germany) was performed
after the manufacturer’s instructions at 24-, 48-, 72-, and
96-hour timepoints. The culture medium was used as a
negative control.
xCELLigence system
The xCELLigence DP device from Roche Diagnostics
(Mannheim, Germany) was used to monitor cell prolifera-
tion in real-time. Respectively 5 × 103 and 1 × 104 MUG-
Myx1 cells were seeded in electronic microtiter plates
(E-Plate™; Roche Diagnostic) and measured for 92 h
with the xCELLigence system according to the instruc-
tions in the user’s manual. Cell density measurements
were performed in quadruplicate with a programmed
signal detection every 20 min. Data acquisition and ana-
lyses were performed with the RTCA software (version
1.2, Roche Diagnostics).Tumour formation in SCID mice
Tumourigenicity of MUG-Myx1
8 week old female/male NOD/SCID/IL-2rγnull (NSG-)
mice (Charles River Laboratories, Sulzfeld, Germany)
were xenotransplanted with the MUG-Myx1 cell line at
passage 65. MUG-Myx1 (4 × 106 cells) were suspended
in 0.2 ml of serum-free medium and subcutaneously
inoculated into the left flank of 10 mice. The mice were
observed daily and the tumour growth was monitored.
All animal work was done in accordance with a protocol
approved by the institutional animal care and use com-
mittee at the Austrian Federal Ministry for Science and
Research (BMWF) (vote 66.010/0160-II/3b/2012).
Tumourigenicity after cell sorting
Under the same conditions, eight mice were xenotrans-
planted. ALDH-stained MUG-Myx1 cells were separated
by FACS analysis and cultured over two weeks. 1 × 106
ALDH1low cells were injected into the right flank, and
1 × 106 ALDH1high cells were injected into the left flank,
of 8-week old female/male NOD/SCID/IL-2rγnull (NSG-)
mice.
Cell cycle analysis
5 × 105 cells were fixed with 70% ice-cold ethanol for
10 min at 4°C. After washing, the cell pellet was re-
suspended in PI-staining buffer (50 μl/ml PI, RNAse A,
Beckman Coulter, US) and incubated for 15 min at 37°C.
Cells were spiked with mononuclear cells (MNC) (positive
diploid population control) then analysed by flow cytome-
try (FACSCalibur, BD Biosciences, San Jose, US). A mini-
mum 10,000 events per sample were acquired and data
were analysed by using CellQuest (BD Biosciences). The
DNA index was calculated by calculating the geometric
mean M2 (MUG-Myx1)/geometric mean M1 (MNCs).
Cell line identification Power Plex® 16 system
Frozen tumour tissue was dissected into small pieces
and re-suspended in 180 μl ATL buffer (Qiagen, Hilden,
Germany). Cell pellets (3.5 × 105) from MUG-Myx1 (p2
and p43) were re-suspended in 200 μl PBS; subsequently
20 μl Proteinase K and 200 μl AL Buffer (Qiagen) were
added. DNA preparations were performed using the
QIAamp DNA Mini kit (Qiagen) in accordance with the
manufacturer’s protocol. After normalizing the DNA,
1 μl of each sample was amplified using the Power Plex®
16 System (Promega, Vienna, Austria) in a 10 μl reaction.
One μl of the product was mixed with Hi-Di formamide
(Applied Biosystems Inc., Foster City, US) and Internal
Lane Standard (ILS600), denatured and fractionated on an
ABI 3730 Genetic Analyzer (Applied Biosystems Inc.).
The resulting data were processed and evaluated using
ABI Genemapper 4.0 (Applied Biosystems Inc.).
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Genomic DNA was isolated from MUG-Myx1 cells using
the QIAmp DNA Kit (Qiagen). The Affymetrix GeneChip
Human Mapping SNP 6.0 array was performed as de-
scribed in the Genome-Wide Human SNP Nsp/Sty 6.0
User Guide (Affymetrix Inc., Santa Clara, US). SNP 6.0
data were imported and normalized using the Genotyping
Console 4.0 program default settings. All samples passing
QC criteria were subsequently genotyped using the
Birdseed (v2) algorithm. We used 60 raw HapMap data
generated with the Affymetrix Genome-Wide Human
SNP Array 6.0 as a reference. Data were obtained from
the Affymetrix website and used for normalization. For
the visualization of the copy number state and LOH, the
Chromosome Analysis Suite 1.1 software (Affymetrix Inc.)
was used.
Aldefluor® assay and separation of the ALDH1high cell
population by FACS analysis
Aldehyde dehydrogenase (ALDH) enzyme activity in vi-
able cells was determined using a fluorogenic dye-based
Aldefluor® assay (Stem Cell Technologies, Grenoble,
France) according to the manufacturer’s instructions.
1 × 106/ml cells were suspended in Aldefluor® assay buffer
containing ALDH substrate (Bodipy-Aminoacetaldehyde)
and incubated for 45 min at 37°C. As a reference control,
the cells were suspended in buffer containing Aldefluor®
substrate in the presence of diethylaminobenzaldehyde
(DEAB), a specific ALDH1 enzyme inhibitor. The brightly
fluorescent ALDH1-expressing cells (ALDH1high) were
detected in the green fluorescence channel (520–540 nm)
of the FACSAria (BD Biosciences) and the data were
analysed using FACS DIVA software (BD Biosciences).
Reverse transcription quantitative real-time -PCR
(RT-qPCR)
RT-qPCR was performed in order to determine the
relative expression of the ABC transporter genes
ABCG2/BCRP1 and ABCB1/MDR1, and the stemness
markers SOX-2, c-Myc, and E-cadherin. Total RNA
was isolated with RNeasy Mini Kit (Qiagen) according
to the manufacturer’s recommended protocol. RNA
quality was analysed using the Agilent RNA 6000 Nano
Kit and the Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA). All RIN values were between 9.8 and
10.0. DNA was digested with 1 U DNase (Fermentas,
St. Leon-Rot, Germany) per μg RNA. One μg RNA was
reverse transcripted using RevertAid cDNA Synthesis
Kit (Fermentas). RT-qPCR reactions were performed in
triplicate using the Platinum SYBR Green Super Mix
with ROX (Invitrogen) on AB7900HT (Applied Biosystems
Inc.). The reference genes glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), β-actin (ACTB) and hypo-
xanthine phosphoribosyltransferase (hprt-n) were usedfor normalization and to demonstrate their stable ex-
pression in different tissues [11]. The following primers
were used for RT-qPCR: QuantiTect primer assays
(Qiagen) for ABCB1 (ID QT00081928), ABCG2 (ID
QT00073206), c-Myc (ID QT00062069), SOX-2 (ID
QT00237601), and E-cadherin (ID QT00080143). The
expression level (CT) of the target gene was normalized
to the reference genes (GAPDH, ACTB, and hprt-n) (ΔCt)
and then the ΔCt of the test sample was normalized to the
ΔCt of the controls (ΔΔCt). Finally, the expression ratio
was calculated with the 2-ΔΔCt –method [12].Statistical analysis
The outcome variables were expressed as mean ± SD.
The student’s unpaired t-test and the exact Wilcoxon’s
test were used to evaluate differences between groups
with the PASW statistics 18 software (IBM Corporation,
Somers, NY). Two-tailed P-values below 0.05 were consid-
ered statistically significant. Graphic data were prepared
with SigmaPlot® (Systat Software Inc., San Jose, US).Results
Establishment of the novel myxofibrosarcoma cell line
MUG-Myx1
Haematoxylin and eosin (HE)-stained slides of the above-
mentioned patient revealed a myxofibrosarcoma G3. The
tumour was composed of tumour areas showing a myxoid
stroma with classic curvilinear tumour vessels, as well
as areas showing a high grade tumour component.
Immunohistochemical (IHC) analysis of the patient’s
tumour revealed only focal SMA positivity, whereas
tests for Desmin, Caldesmon, S100, CD34, EMA, and
Pan-CK were negative (Figure 1A).
After crushing and enzymatically digesting the tumour
tissue, the cells were successfully grown. During the
course of cultivation, the cells were regularly cryopre-
served. Cells grew to be adherent as a monolayer. The
cells were passaged more than 100 times and were in
culture for 12 months, however, the morphology of
MUG-Myx1 cells did not change significantly during
long-term cultivation. HE staining showed cells with
prominent nucleoli and abundant cytoplasm (Figure 1B).
The mesenchymal origin of the tumour was confirmed
by high vimentin expression (Figure 1C).
In order to elicit the growth behaviour of the cells,
they were detected in triplicate with the xCELLigence
System (Roche Applied Science). Using the RTCA 1.2.1
software (ACEA Biosciences Inc., San Diego, US), the
population doubling time of the MUG-Myx1 cells was
calculated at 24 h at 37°C in a humidified atmosphere
(Figure 1D). Additionally, the growth behaviour of three
different cell counts was investigated with the MTS
assay after 24–96 hours (Figure 1E).
Figure 1 Establishment and characterization of the myxofibrosarcoma cell line MUG-Myx1. (A) IHC analysis on patient tumour tissue
showed poorly differentiated tumour components (left) in connection with better differentiated tumour areas with myxoid stroma and curvilinear
blood vessels (right). (B) The hematoxylin and eosin (H&E) staining of the MUG-Myx1 cell line showed spindle and multinucleated tumour cells.
(C) Strong expression of Vimentin of the MUG-Myx1 cell line confirmed the mesenchymal origin of the tumour cells; nuclei were stained with
DAPI. (D) Dynamic proliferation curves for MUG-Myx1; 5 × 103 and 1 × 104 cells were seeded per well and measured with the xCELLigence system.
(E) MTS proliferation analysis revealed a 24 h doubling time. (F) The DNA index of 1.15 indicated hyperdiploid tumour cells (left). Gating strategy
of cell cycle analysis, to exclude doublets from the total population (right). (G) MUG-Myx1 Tumour formation in NOD/SCID/IL-2rγnull (NSG-) mice.
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analyses were carried out: definition of the ploidy status,
tumourigenicity in NOD/SCID mice, short tandem re-
peat (STR) analysis, copy number variation (CNV), and
genotype/loss-of-heterozygosity (LOH) analysis. The
DNA index was calculated by analysing the geometric
mean M2 (MUG-Myx1) 229.0/geometric mean M1
(MNCs) 199.0. This results in DNA index of 1.15, which
means the cells were hyperdiploid (Figure 1F). MUG-
Myx1 (p65) successfully formed tumours in 8 of 10
transplanted mice. The take rate was very fast; small
nodules were palpable 2 weeks after inoculation, and
the tumours grew to 1.2–2.3 cm in diameter 5 weeks
later. The remaining two mice died. One representative
mouse and its accompanying tumour is shown in Figure 1G
(n = 8). The success rate of MUG-Myx1 cells growing inNOD/SCID/IL-2rγnull (NSG-) mice was 80%. For the
identification of the cell line, we used the Power Plex® 16
System. The frozen primary parental tumour tissue and
the MUG-Myx1 cell line (p2 and p43) showed the same
STR profile at the markers D3S1358, TH01, D21S11,
D18S51, Penta E, D5S818, D13S317, D7S820, D16S539,
CSF1PO, Penta D, Amelogenin, D8S1179, TPOX and
FGY. All values are summarized in Table 1.
Cytogenetic findings
Chromosomal copy number analysis
A CNV and LOH analysis of the cell line reveals gains,
losses and copy neutral LOHs (uniparental disomy), as
are summarized in Figure 2 and Tables 2 and 3. Typically
myxofibrosarcoma gain and/or amplification were mapped
to 7p21.3-q31.1, q31.1-q31.33, q33-q36.2, p21.3, p21.2,
Table 1 STR genotype of primary tumour, a low passage
(p2) and a high passage (p43) MUG-Myx1 cell line
Tumour tissue p2 p43
D3S1358 17,18 17,18 17,18
TH01 6,8 6,8 6,8
D21S11 26,31 26,31 26,31
D18S51 17,24 24 17,24
Penta E 12,17 12,17 12,17
D5S818 13 13 13
D13S317 9,12 12 9,12
D7S820 10,11 10,11 10,11
D16S539 12,13 12 12,13
CSF1PO 11 11 11
Penta D 9,12 9,12 9,12
AMEL XY XY XY
vWA 15,19 15,19 15,19
D8S1179 13 13 13
TPOX 8 8 8
FGA 18,20 18,20 18,20
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q36.2-q36.3. These loci are respectively known to harbour
tumour-associated genes, including TIF, BRAF, MLL3,
SMO, and MET. However, losses tended to be small
changes, which mapped only to chr5 q34 and chr8 p11.22,
and acquired uniparental disomy (aUPD), also known as
copy number neutral LOH, occurs prominently in the cell
line (Figure 2). Typical LOH for myxofibrosarcoma on
chr5 q21 were found.Figure 2 Cytogenetic findings. Overview of chromosomal CNVs and LOH
represents LOHs (violet mark), the second line represents gains (blue mark)MUG-Myx1 cell line displays a considerable fraction of
ALDH1high stem-like cells
We used the Aldefluor® assay followed by FACS analysis
to assess the presence and quantity of ALDH1high cell
populations in the MUG-Myx1 cell line. In order to set
a marker for ALDH1high cells, diethylaminobenzaldehyde
(DEAB) control cells were used to ensure the accuracy
of the analysis. MUG-Myx1 cells in a low passage (p17)
and in a high passage (p87) (Figure 3A) were treated in
the presence of the ALDH1 inhibitor DEAB or stained
with Aldefluor® reagent, which are defined as ALDH1low
and ALDH1high cells. Sorting experiments were per-
formed a minimum of seven times on each passage. The
amount of ALDH1high cells given on average ± SD was
6.16 ± 1.75% for the lower passage (n = 7) and 4.53 ±
1.55% for the higher passage of MUG-Myx1 (n = 8)
(Figure 3B).
The mRNA expression of ABC transporter and stemness
marker are upregulated in MUG-Myx1 ALDH1high cells
The relative expression of two major drug transporters
ABCG2/BCRP1 and ABCB1/MDR1 were determined
by RT-qPCR (n = 7). The ALDH1high population of
MUG-Myx1 demonstrated, with statistical significance,
an increased expression level of ABCB1 (ratio 1.43 ± 0.22;
p = 0.0046) compared to ALDH1low control cells (ratio = 1),
whereas the increase of ABCG2 was not significant (ratio
1.57 ± 0.69) (Figure 3C). Furthermore, we investigated
whether ALDH1high cells are enriched for expression of
genes that have been postulated to play key roles in stem
cell biology, such as c-Myc, E-cadherin, and SOX-2.
Quantitative RT-PCR showed a significantly increaseds observed for the passage 43 of the MUG-Myx1 cell line. The first line
and losses (red mark).
Table 2 Gain and Loss at chromosomal regions and










3 Gain 1 p36.13 p36.13
3 Gain 1 q21.1 q21.1 PDE4DIP
3 Gain 2 q32.1 q32.1
4 Gain 2 p11.2 p11.2
3 Gain 3 q26.31 q26.31
4 Gain 3 q26.1 q26.1
4 Gain 4 q13.2 q13.2
1 Loss 5 q34 q34
3 Gain 7 p22.3 p21.3 CARD11;PMS2
3 Gain 7 q21.3 q31.1
3 Gain 7 q33 q36.2 TRIM24;
KIAA1549;BRAF;
EZH2;KMT2C
3 Gain 7 p21.3 p21.2 ETV1
3 Gain 7 p21.2 p21.2
3 Gain 7 p14.1 q11.23 IKZF1;EGFR;
SBDS;ELN;HIP1
3 Gain 7 q31.33 q33 SMO




3 Gain 7 q33 q33 CREB3L2
3 Gain 7 q11.23 q21.3 AKAP9;CDK6
3 Gain 7 q31.1 q31.33 MET
3 Gain 7 q36.2 q36.3 MNX1
3 Gain 8 p23.1 p23.1
1 Loss 8 p11.22 p11.22
3 Gain 10 q11.22 q11.22
4 Gain 10 q25.1 q25.1
3 Gain 10 q11.22 q11.22
3 Gain 12 p13.31 p13.31
3 Gain 14 q32.33 q32.33
3 Gain 15 q11.2 q11.2
3 Gain 15 q11.2 q11.2
4 Gain 15 q11.1 q11.2
3 Gain 17 q21.31 q21.31
3 Gain 21 p11.1 q11.2
3 Gain 22 q11.22 q11.22
3 Gain 22 q11.23 q11.23
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1.75 ± 0.39; p = 0.0051). Similarly, a slight but not signifi-
cant increase in the expression of c-Myc (ratio 1.28 ± 0.49)
and E-cadherin (ratio 1.58 ± 0.79) in the ALDH1high
fraction was observed (n = 7) (Figure 3C).MUG-Myx1 ALDH1A1positive cells show higher
tumourigenicity and proliferation
After separation by FACS Aria (BD Bioschiences), MUG-
Myx1 cells derived from the 87th passage successfully
formed transplanted tumours in all eight transplanted
mice. After five weeks, the ALDH1high cells formed signifi-
cantly larger tumours with the same cell amount and same
latency period as in the mice injected with ALDH1low
cells. Furthermore, they differed significantly in their
tumour weights (0.68 ± 0.41 g vs 1.11 ± 0.47 g; p = 0.012;
n = 8) (Figure 3D). Successful engraftment was deter-
mined by pathological examination of the formalin-
fixed, paraffin-embedded (FFPE) material of the tumour
samples. High mitotic rate and high proliferative index
were confirmed by IHC with the proliferation marker
Ki-67. Using the ImageScope software, Ki-67 tissue
samples ALDH1low and ALDH1high tumour slides were
quantified after IHC staining. ALDH1high tumours from
all eight mice displayed an increased proliferation level
as compared to ALDH1low tumours (Ki-67 positivity:
0.206 ± 0.039 vs 0.067 ± 0.041; p = 1.11E-07; n = 8). A
representative staining of one pair of tumours is shown
and summarized in Figure 3E.
Discussion
Myxofibrosarcoma is a malignant neoplasm with variably
prominent myxoid stroma, cellular pleomorphism, and a
distinct curvilinear vascular pattern and represents the
most common sarcoma in elderly patients, with a slight
predominance in males [1]. Local, often repeated recur-
rences, unrelated to histological grade, occur in up to
50–60% of cases [2,13-15].
To develop novel therapeutic interventions, it is highly
desirable to establish new human primary cell lines to
elucidate the molecular determinants correlated with
tumour invasion and metastatic spread. The established
MUG-Myx1 cell line can be maintained in long-term
cultures with a 24-hour doubling time. The parent
tumour and the cultured tumour cells clearly demon-
strated the typical morphological and histological features
of myxofibrosarcoma. In order to characterize our MUG-
Myx1 cell line, we have determined the DNA ploidy sta-
tus. Aneuploidy is defined as an abnormal chromosome
number that deviates from a multiple of the haploid as a
consequence of gradual gains or losses of chromosomes in
cancer cells that evolve into unstable complex karyotypes
[16-18]. MUG-Myx1 cells revealed a DNA index of
1.15, which defined its hyperdiploid status. This result
is in concordance with Huang et al., who found aneu-
ploid or tetraploid DNA ploidy status in 75 well-
characterized myxofibrosarcomas [4]. One key feature
of cancer cells versus normal cells is chromosome in-
stability, which is proposed to be critical for the initi-
ation of tumourigenesis [19]. It was for this reason that








LOH 1 p36.22 p36.21
LOH 1 p33 p32.3 CDKN2C
LOH 2 p23.1 p22.3
LOH 2 q21.3 q22.1
LOH 2 q24.3 q24.3
LOH 2 q32.3 q32.3
LOH 2 p16.1 p16.1
LOH 2 q12.3 q13
LOH 3 q13.13 q13.13
LOH 3 q13.12 q13.13
LOH 3 p21.2 p21.1 BAP1
LOH 4 q22.3 q23 RAP1GDS1
LOH 4 p15.1 p15.1
LOH 4 q31.3 q31.3
LOH 5 p13.1 p13.1
LOH 5 q23.1 q23.1
LOH 5 q23.3 q31.1 ACSL6
LOH 5 q21.1 q21.1
LOH 6 q24.3 q24.3
LOH 6 p22.2 p22.1
LOH 6 p21.31 p21.31 FANCE
LOH 7 p11.2 p11.2 EGFR
LOH 7 q32.1 q32.1
LOH 7 q11.22 q11.22
LOH 7 q31.1 q31.1
LOH 7 q31.31 q31.31
LOH 8 p11.21 p11.1 HOOK3
LOH 9 p24.3 p21.1 JAK2;CD274;CD273;
NFIB;PSIP2;MLLT3;
CDKN2a(p14)
LOH 10 q22.1 q22.2
LOH 10 q26.3 q26.3
LOH 10 q24.32 q24.32 NFKB2
LOH 11 p15.4 p15.4
LOH 11 q13.4 q13.4
LOH 11 p11.2 p11.12
LOH 12 q24.33 q24.33
LOH 12 p11.1 p11.1
LOH 12 q21.2 q21.31
LOH 12 q24.11 q24.13 ALDH2
LOH 13 q21.1 q21.1
LOH 13 q31.1 q31.1
LOH 14 q21.1 q21.2
LOH 15 q15.1 q15.3
LOH 15 q21.1 q21.1
Table 3 Loss of heterozygosity of the myxofibrosarcoma
cell line MUG-Myx1 (Continued)
LOH 15 q24.3 q24.3
LOH 15 q21.1 q21.2
LOH 16 q11.2 q12.1
LOH 16 p11.2 p11.2
LOH 17 q22 q23.2 CLTC
LOH 19 q13.12 q13.13
LOH 20 q11.22 q11.22
LOH 20 p11.21 p11.1
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rity of MUG-Myx1 by SNP analysis. Gains in gene copy
number drive the expression of oncogenes, whereas de-
creased gene dosage by hemizygous and/or homozygous
deletion result in the inactivation of tumour suppressor
genes [20]. Mertens et al. showed that the only recur-
rent gain involves chromosome 7, whereas losses pri-
marily affect chromosomes 1, 3, 5, 6, 10, 12, 16, 17, and
19 [21]. There is mounting evidence that regional gains
and/or high-level amplifications on chromosomal arm
7q are recurrently found in various types of bone and
soft tissue sarcomas, including myxofibrosarcomas [22-26].
Interestingly, overexpression of the oncogene MET in myx-
ofibrosarcoma, as a frequent event, was strongly related to
higher grades and seems to have a causative function in
conferring an aggressive phenotype [27]. Tsai et al. showed
a strong correlation between CDK6 and MET gene copies
on 7q in primary myxofibrosarcomas. CDK6 protein over-
expression and gene amplification were both univariately
associated with worse outcomes [28].
MUG-Myx1, especially, showed gains on chromosome
7, including at 7q31.1, the MET location, and can there-
fore represent an in vitro model for MET-target therapy
investigations. Furthermore, Tuna et al. determined the
frequency and distribution patterns of aUPD in soft tis-
sue sarcoma and identified aUPD in myxofibrosarcoma
at 1p35.1-p34.2 and 16q23.3-q24.1, which we were able
to confirm in our newly established cell line [29]. Due
to the fact that metastatic myxofibrosarcomas are often
refractory to current treatment strategies and constitute
the primary cause of sarcoma-related death [30,31], we
also wanted to investigate stem-like cells in the MUG-
Myx1 cell line. Based on the current CSC hypothesis,
only a small subpopulation within the heterogeneous
tumour population is capable of initiating and re-initiating
tumours. The concept of CSCs was based on the observa-
tion that when cancer cells of many different types were
assayed for their proliferative potential in various assays
in vitro and in vivo, only a minority of cells showed ex-
tensive proliferation [32]. One widely accepted method
for identifying CSCs is based on the enzymatic activity
of ALDH1, a detoxifying enzyme responsible for the
Figure 3 Characterization of the ALDH1high subpopulation. (A) Aldehyde dehydrogenase 1 (ALDH1) expression in MUG-Myx1 cells using the
Aldefluor® assay. (B) ALDH1 expression in percentage of gated cells. (C) The normalized expression levels from ABC transporter genes and
stemness markers in ALDH1high cells compared to ALDH1low control cells (black bar). (D) SCID mice ALDH1low and ALDH1high tumours differed
significantly in their tumour weights. (E) The IHC analysis using anti-Ki-67 proliferation marker revealed an increased proliferation level of
ALDH1high as compared to ALDH1low mouse tumours.
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http://www.biomedcentral.com/1471-2407/13/563oxidation of intracellular aldehydes. The ground-breaking
work of Ginestier et al. showed the potential applicability
of quantifying ALDH activity in solid tumours [7]. In the
future, ALDH activity could be used successfully as a CSC
marker for many cancers, including soft tissue sarcomas
[10,33-36]. The present results demonstrate that MUG-
Myx1 cells contained a distinctive fraction of ALDH1high
cells, interestingly in a higher percentage in the lower
passage (p17). Our group observed that the number of
ALDH1high decreased during the course of cultivation.
The higher expression of ABC transport proteins in
stem cells as compared to non-stem cells results in a
higher resistance of the stem cells to the toxic effects of
chemotherapy drugs [37,38]. We analysed the mRNA
expression of the two major drug transporters ABCG2/
BCRP1 and ABCB1/MDR1. In the present study, both
drug transporters were upregulated in MUG-Myx1ALDH1high cells. Thus, these genes may potentially be
ideal targets for clinical cancer therapy. Because c-Myc
has recently been recognized as an important regulator
of stem cell biology, it may serve as a link connecting
malignancy and “stemness” [39]. The introduction of c-
Myc with other transcription factors (including SOX-2)
generates the induction of pluripotent stem cells from
differentiated cells [40]. Our quantitative RT-PCR
data showed increased expression of c-Myc, SOX-2, and
E-caherine in the ALDH1high population. The ALDH1high
population showed a significantly higher tumour forma-
tion capacity and proliferation rate, consistent with the
characteristics of the high ALDH1 activity phenotype in
other cancer cells [41,42], which may indicate that
ALDH1high cells are partially responsible for tumour
metastasis and recurrence and should be targeted during
the cancer therapy.
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In conclusion, the well-characterized myxcofibrosarcoma
cell line MUG-Myx1 will be a useful tool to gain further
insights into the pathogenesis of myxofibrosarcoma and
explore new treatment options. Targeting stem-like cells
with increased ALDH1 expression may especially facili-
tate the development of better treatment for patients
suffering from myxofibrosarcomas.
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